News | News By Subject | News by Disease News By Date | Search News

Oral Mucositis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Sucampo (SCMP) Terminates Development of Cobiprostone Following Phase II Data     7/11/2016
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Celgene International Sárl (CELG)'s Oral Anti-Cancer Therapy Pomalidomide Gets European Commission (EC) Approval     8/9/2013
Access Pharmaceuticals (ACCP) Announces Interim Data From MuGard Phase 4 Clinical Trial in Oral Mucositis     4/17/2012
SciClone Pharmaceuticals, Inc. (SCLN) to Discontinue Development of SCV-07 Oral Mucositis Trial     3/7/2012
ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer     3/6/2008
MGI PHARMA, INC. (MOGN) Announces Publication Of Phase 3 Data For Saforis™ (Glutamine) Powder In UpTec™ For Oral Suspension In Cancer - Primary Endpoint Was Met     1/18/2007
Cytogen Corporation (CYTO) Acquires North American Marketing Rights To CAPHOSOL(R) For Treatment Of Both Oral Mucositis And Dry Mouth     10/11/2006
CuraGen Corporation (CRGN) Confirms Failed Phase II Results For Velafermin; Shares Drop     2/21/2006
CuraGen Corporation (CRGN) Drug For Oral Mucositis Misses Goal     12/13/2005
Amgen (AMGN) Release: FDA Approves Kepivance For Severe Oral Mucositis In Cancer Patients Undergoing Bone Marrow Transplant; Pivotal Phase 3 Study Published In This Week's New England Journal Of Medicine     12/16/2004
CuraGen Corporation (CRGN) Receives Fast Track Designation For CG53135     12/2/2004
GeoPharma, Inc. (GORX) Receives FDA Approval For Mucotrol(TM); Manages Mucositis Caused By Radiation And Chemotherapy Required In Cancer Treatment; Shares Surge     12/1/2004
MGI Pharma (MOGN) To Acquire Aesgen, Inc. -- Saforis For Oral Mucositis Bolsters MGI's Oncology Supportive Care Franchise; $32 Million In Cash     9/1/2004

News from Around the Web

Press Releases
Oragenics (OGEN) Doses First Patient In Phase II Clinical Trial Of AG013 For Oral Mucositis     8/31/2017
Soligenix (SNGX) Release: Complete Efficacy And Long-Term Follow-Up Safety Results From SGX942 Phase II Oral Mucositis Clinical Trial To Be Presented At The 2017 Multinational Association For Supportive Care In Cancer Conference     6/19/2017
Cellceutix (CTIX) CEO Discusses Brilacidin Following Interim Trial Results For Treating Oral Mucositis And Inflammatory Bowel Disease     4/10/2017
Cellular Biomedicine Group (CBMG) Awarded $2.29 Million Grant From The California Institute For Regenerative Medicine (CIRM) To Fund AlloJoin Allogeneic Stem Cell Therapy For Knee Osteoarthritis (KOA) In The U.S.     2/27/2017
Oragenics (OGEN) Receives Supportive FDA Feedback For Initiating A Phase II Study Protocol For Oral Mucositis Treatment     8/30/2016
Mundipharma AG Release: Multinational ADOPT Study Seeks Further Improvement In Management Of Oral Mucositis     6/28/2016
ASCO2016: Galera Announces Presentation At ASCO Of Positive Results From Study Of GC4419 For The Reduction Of Severe Oral Mucositis     6/6/2016
Oragenics, Inc. (OGEN) Announces Positive Results From Confirmatory Animal Study Of AG013 For Treatment Of Oral Mucositis And Plans To Finalize Phase 2 Clinical Trial Protocol     5/3/2016
Allovate Announces Positive Results Of Proof-Of-Concept Study Of Oral Mucosal Immunotherapy (OMIT)     4/25/2016
Intrommune Therapeutics Announces Positive Results Of Proof-Of-Concept Study Of Oral Mucosal Immunotherapy (OMIT) Platform For The Treatment Of Allergies     4/25/2016
Intrommune Therapeutics Announces Issuance Of U.S. Patent Covering Oral Mucosal Immunotherapy For Food Allergy     3/1/2016
Onxeo Announces Data Demonstrating High Patient Compliance And Acceptability Of Validive For Treatment Of Severe Oral Mucositis     10/22/2015
Soligenix (SNGX) Announces Completion Of Patient Enrollment Into Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients (1)     8/31/2015
FDA Grants Fast Track Designation To Sucampo (SCMP)'s Cobiprostone For Oral Mucositis     5/8/2015
Onxeo : Oral Presentation Of Phase II Trial Results Of Validive At The MASCC/ISOO International Symposium     5/6/2015